Synapse - Find an Expert

5913 Results

Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors

Meeting Abstract

Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
Blood (2020)

Fulltext@MSK | Save

Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia

Meeting Abstract

Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
Blood (2020)

Fulltext@MSK | Save

Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era

Meeting Abstract

Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
Blood (2020)

Fulltext@MSK | Save

LSD1 inhibitor CPI-482 shows efficacy and prolongs survival in mouse models of AML and post-MPN AML in the context of constitutive JAK-STAT pathway activation

Meeting Abstract

Rampal, R. K.; McGrath, J. P.; Krishnan, A.; Li, B.; Xiao, W.; Nikom, D.; Wang, J.; Levine, R. L.; Trojer, P.
Blood (2020)

Fulltext@MSK | Save

Analysis of the global methylation profile of accelerated and blast phase myeloproliferative neoplasms and its association with response to decitabine-based therapy

Meeting Abstract

Rampal, R. K.; Yang, Q.; Koche, R. P.; McGovern, E.; Famulare, C.; Weinberg, R. S.; Mascarenhas, J.; Levine, R. L.; Hoffman, R.; Figueroa, M. E.
Blood (2020)

Fulltext@MSK | Save

Immunophenotypic lineage assessment by multiparameter flow cytometry provides more precise MDS prognosis

Meeting Abstract

Onyekwere, I.; Garcia, J. P.; Menghrajani, K.; Chan, A.; Famulare, C.; Patel, M. A.; Philip, J.; Tallman, M. S.; Klimek, V. M.; Levine, R. L.; more...
Blood (2020)

Fulltext@MSK | Save

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save

Loss of LKB1/(STK11) facilitates leukemic progression of the myeloproliferative neoplasms

Meeting Abstract

Marinaccio, C.; Suraneni, P. K.; Celik, H.; Volk, A.; Wen, J. Q.; Ling, T.; Lasho, T.; Koche, R. P.; Famulare, C.; Stein, B. L.; more...
Blood (2020)

Fulltext@MSK | Save

Phase Ib trial with dose expansion of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in patients with refractory/recurrent primary central nervous system lymphoma (PCNSL) and refractory/recurrent secondary central nervous system lymphoma (SCNSL)